Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PharmAbcine, Inc. (208340.KQ)

KOSDAQ - KOSDAQ Delayed Price. Currency in KRW
3,260.00-50.00 (-1.51%)
At close: 03:30PM KST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,310.00
Open3,380.00
Bid3,250.00 x 0
Ask3,280.00 x 0
Day's Range3,215.00 - 3,380.00
52 Week Range3,215.00 - 3,380.00
Volume116,359
Avg. VolumeN/A
Market Cap22.406B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 208340.KQ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      PharmAbcine to participate in Jefferies 2022 London Healthcare Conference

      PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited at upcoming Jefferies 2022 London Healthcare Conference. Jefferies is scheduled to be held in London from November 15-17, 2022.

    • PR Newswire

      PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

      PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston.

    • PR Newswire

      PharmAbcine to Participate in BIO-Europe 2022

      PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 – 26, 2022.

    Advertisement
    Advertisement